Disease · MONDO_0016236

kaposiform hemangioendothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kaposiform hemangioendothelioma. Diseases, record MONDO_0016236. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016236

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kaposiform hemangioendothelioma; Open Targets
Open Targets ID: MONDO_0016236; Open Targets
MeSH: C537007; MeSH
NCI Thesaurus: C27510; NCI Thesaurus
Orphanet: ORPHA:2122; Orphanet
Highest stage of its drugs: Phase 2/3, for 1 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SIROLIMUS	CHEMBL413	Small molecule	Phase 2/3	ClinicalTrials.gov	7	7	7	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2/3	https://conductscience.org/library/genes/2280	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02110069	A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors	Phase 2	4	2021-05-24	Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma	SIROLIMUS, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT07131644	Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma	Phase 2	120		Kaposiform Hemangioendothelioma	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04775173	Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.	Phase 2	79		Kaposiform Hemangioendothelioma	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04056962	Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma	Phase 2	50		Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma	TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03188068	Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma	Phase 2	30		Kaposiform Hemangioendothelioma, Kasabach Merritt Phenomenon	PREDNISOLONE, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04598204	Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients	Phase 2/3	30		Vascular Anomalies	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT05324384	Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma	Phase 2	30		Hemangioendothelioma	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04409691	SCMC Trial on KHE With KMP (V.2020)	Phase 1	20		Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP)	SIROLIMUS	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vincristine vs Sirolimus: deaths from any cause	0 of 2	0 of 2	4	NCT02110069	Trial comparisons
Vincristine vs Sirolimus: serious adverse events	1 of 2	1 of 2	4	NCT02110069	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40107509	RESULT	1	PubMed
39831682	RESULT	1	PubMed
36916140	RESULT	1	PubMed
35030255	RESULT	3	PubMed
34273457	RESULT	1	PubMed
33580918	RESULT	1	PubMed
32014025	RESULT	2	PubMed
31489702	RESULT	2	PubMed
31030813	RESULT	1	PubMed
30396415	RESULT	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016236

GET https://conductscience.org/api/diseases/v1/MONDO_0016236/drugs

API reference For AI assistants